ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2018

Summary

Eli Lilly and Company reported a solid third quarter of 2018, with revenue increasing by 7% year-over-year to $6,061.9 million, driven primarily by volume growth in key pharmaceutical products. Diluted Earnings Per Share (EPS) also saw a significant increase, more than doubling to $1.12 compared to $0.53 in the prior year period. This performance was supported by strong demand for newer products like Trulicity, Taltz, and Basaglar, alongside continued contributions from established products. The company also made significant strategic moves during the quarter, including the initial public offering (IPO) of its Elanco Animal Health business, which is expected to drive future shareholder value. While facing ongoing challenges from patent expirations and generic competition for some older products, Lilly's robust pipeline and focus on innovative therapies appear to be yielding positive results, as reflected in the overall financial growth. Management expressed confidence in the company's ability to fund ongoing operations, dividends, and share repurchases through operational cash flow.

Key Highlights

• 1Revenue increased 7% to $6.06 billion, driven by volume growth in key pharmaceutical products.
• 2Diluted EPS more than doubled to $1.12 from $0.53 in the prior year period.
• 3Successful initial public offering (IPO) of Elanco Animal Health business completed.
• 4Strong performance from Trulicity, Taltz, and Basaglar contributed significantly to revenue growth.
• 5Acquired IPR&D charges decreased significantly compared to the prior year, positively impacting net income.
• 6Asset impairment, restructuring, and other special charges were also substantially lower year-over-year.
• 7Company repurchased $3.05 billion of shares during the nine months ended September 30, 2018, under a new $8 billion repurchase program.

Frequently Asked Questions